ArticleDiabetes technology & therapeutics2017
Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology.
Article in Diabetes technology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04275479 (Endocrine Diabetes Screening in Patients With Shwachman-Diamond Syndrome DIABETES/ ENDOCRINE SURVEILLANCE IN SDS), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Endocrine Diabetes Screening in Patients With Shwachman-Diamond Syndrome DIABETES/ ENDOCRINE SURVEILLANCE IN SDS
Who cites it
63 citing papers in PubMed.
- Clinical validation of continuous glucose monitoring in glycemic management of critically ill sepsis patients: A prospective randomized clinical study.The Journal of international medical research · 2026Trial
- Effects of intake of four types of snack with different timings on postprandial glucose levels after dinner.European journal of nutrition · 2023Trial
- Trial
- Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.Acta diabetologica · 2020Trial
- The Impact of Interfering Substances on Continuous Glucose Monitors: Part 2: Marketed Continuous Glucose Monitoring Designs, Labeled Interfering Substances, and Design Mitigations.Journal of diabetes science and technology · 2026Review
- International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring.Diabetes, obesity & metabolism · 2026Review
- Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction.Science translational medicine · 2026Article
- A deep learning-derived digital biomarker of dysglycemia and its association with genetic risk of type 2 diabetes.npj metabolic health and disease · 2025Article
- The Role of Calibration Practices in Optimizing Continuous Glucose Monitor Accuracy in Critically Ill Patients.CHEST critical care · 2025Article
- The Convergence of Polymer Science and Predictive Modeling for Noninvasive Glucose Monitoring.Pharmaceutics · 2025Review
- Continuous Nicotine Monitors for Personal Nicotine Pharmacokinetics: A Receptor-Aware Research Agenda.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Review
- Consensus statement on standardizing CGM evaluation metrics in Latin America: an expert approach.Diabetology & metabolic syndrome · 2025Article
- Dynamic Interference Testing-Unexpected Results Obtained with the Abbott Libre 2 and Dexcom G6 Continuous Glucose Monitoring Devices.Sensors (Basel, Switzerland) · 2025Article
- Novel interfaces for internet of wearable electrochemical sensors.RSC advances · 2024Review
- Article
- Long-Term Evaluation of Inserted Nanocomposite Hydrogel-Based Phosphorescent Oxygen Biosensors: Evolution of Local Tissue Oxygen Levels and Foreign Body Response.ACS applied bio materials · 2024Article
- Flap Monitoring Using Interstitial Fluid Glucose Measurements.Plastic surgery (Oakville, Ont.) · 2024Article
- Article
- Miniaturized Capsule System Toward Real-Time Electrochemical Detection of HAdvanced healthcare materials · 2024Article
- Quality of Life and Glucose Regulation in Pediatric Patients with Type 1 Diabetes: A Study in the Ningxia Hui Autonomous Region.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of commercially available continuous glucose monitors for diabetes management requires sensor calibrations, which until recently are exclusively performed by the patient. A new development is the implementation of factory calibration for subcutaneous glucose sensors, which eliminates the need for user calibrations and the associated blood glucose tests. Factory calibration means that the calibration process is part of the sensor manufacturing process and performed under controlled laboratory conditions. The ability to move from a user calibration to factory calibration is based on several technical requirements related to sensor stability and the robustness of the sensor manufacturing process. The main advantages of factory calibration over the conventional user calibration are: (a) more convenience for the user, since no more fingersticks are required for calibration and (b) elimination of use errors related to the execution of the calibration process, which can lead to sensor inaccuracies. The FreeStyle Libre
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.